Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience

Table 2 Comparative clinical trial data with ASAQ Winthrop (as of December 2010)

Comparator drug	Country, Reference	Patients	Patients receiving ASAQ Winthrop
Non-fixed combination of aretsunate + amodiaquine	Burkina Faso [5]	Children < 5 years	375
Amodiaquine	India [SP]	Children and adults	201
Artemether-lumefantrine	Senegal, Mali, Cameroon, Madagascar [8]	Children and adults	629
	Benin [13]	Children < 10 years	90
	Liberia [14]	Children < 5 years	150
	Liberia [15]	Children and adults	496
	Senegal [16]	Children and adults	184
	Colombia [SP]	Adults	105
	Uganda [SP]	Children < 5 years	200
Artemether-lumefantrine and DHA-piperaquine	Burkina Faso, Gabon, Mozambique, Nigeria, Rwanda, Uganda, Zambia [17]		1002
Total			3432

ISSN: 1475-2875